Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)
The aim of this exploratory phase 3 study is to investigate the effect of once-weekly subcutaneous semaglutide on central (cerebrospinal fluid [CSF]) and peripheral (blood) inflammation using single-cell transcriptomics (i.e. gene expression in individual cells) to expand the molecular understanding of semaglutide and Alzheimer’s disease (AD).
Authors
- Kathrine E. Attfield (ORCID: https://orcid.org/0000-0003-3387-521X)
- Kristian Steen Frederiksen (ORCID: https://orcid.org/0000-0001-5124-4417)
- Ibrahim Malik (ORCID: https://orcid.org/0000-0003-2048-2097)
- Rose Jeppesen (ORCID: https://orcid.org/0000-0002-9984-2202)
- Lotte Bjerre Knudsen (ORCID: https://orcid.org/0000-0002-2439-7116)
- Marie A. Bentsen (ORCID: https://orcid.org/0000-0002-2561-2308)
- Paul Mystkowski
- Peter Johannsen (ORCID: https://orcid.org/0000-0003-4570-8881)
- Giovanni B. Frisoni (ORCID: https://orcid.org/0000-0001-7075-7082)
Institutions
- University of Geneva (CH)
- University of Copenhagen (DK)
- Novo Nordisk (Denmark) (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Novo Nordisk (United Kingdom) (GB)
- Cognitive Neuroimaging Lab (FR)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211162
- Citations
- 1
- Primary Topic
- Cancer-related cognitive impairment studies
- Type
- article
- Field-Weighted Citation Impact
- 1.52